Nesina (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Date: July 31, 2013
Pages: 46
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NC599168565EN

Download PDF Leaflet

Nesina (Type 2 Diabetes) - Forecast and Market Analysis to 2022
Nesina (Type 2 Diabetes) - Forecast and Market Analysis to 2022


GlobalData has released its new report, “Nesina (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Alogliptin (Nesina) was developed by Takeda Pharmaceutical Company and obtained regulatory approval in Japan in 2010. The FDA approved Nesina along with the combinatorial drugs Kazano (combination of alogliptin and metformin) and Oseni (combination of alogliptin and pioglitazone) at the beginning of 2013. The FDA had previously rejected the drug's initial application in 2008, citing concerns about heart attacks.

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Nesina including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Nesina for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Nesina performance
  • Obtain sales forecast for Nesina from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

1.1 List of Tables
1.2 List of Figures


2.1 Catalyst
2.2 Related Reports


3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
  3.1.3 Prognosis
  3.1.4 Quality of Life
3.2 Symptoms


4.1 Treatment Overview
  4.1.1 Diagnosis and Referrals
  4.1.2 Treatment Guidelines


5.1 Overview
5.2 Strategic Competitor Assessment


6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast


7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
  7.4.1 Diagnosed Type 2 Patients
  7.4.2 Percent Drug-Treated Patients
  7.4.3 Drugs Included in Each Therapeutic Class
  7.4.4 Launch and Patent Expiry Dates
  7.4.5 General Pricing Assumptions
  7.4.6 Individual Drug Assumptions
  7.4.7 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 About the Authors
  7.6.1 Analyst II - CVMD
  7.6.2 Therapy Director - CVMD and Infectious Disease
  7.6.3 Global Head of Healthcare
7.7 About GlobalData
7.8 Disclaimer


Table 1: Symptoms of Type 2 Diabetes
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
Table 3: Treatment Guidelines for Type 2 Diabetes
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012
Table 6: Product Profile - Nesina
Table 7: Nesina SWOT Analysis, 2012
Table 8: Global Sales Forecasts ($m) for Nesina and Oseni and Kazano, 2012-2022
Table 9: Key Launch Dates
Table 10: Key Patent Expiries
Table 11: Number of High-Prescribing Physicians Surveyed


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy
Skip to top

Ask Your Question

Nesina (Type 2 Diabetes) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: